Welcome to our dedicated page for EVTCY news (Ticker: $EVTCY), a resource for investors and traders seeking the latest updates and insights on EVTCY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EVTCY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EVTCY's position in the market.
Rhea-AI Summary
Evotec SE (EVT) has received a US$ 2.5 million grant from the Bill & Melinda Gates Foundation for its teratogenicity platform and joins the foundation's Global Health Discovery Collaboratory. The grant provides GHDC members access to Evotec's high-throughput teratogenicity platform at no extra cost, enabling cost-effective de-risking of drug candidates early in the discovery process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
-
News
Rhea-AI Summary
Evotec SE (EVT) partners with Charité Universitätsmedizin Berlin to create a molecular patient database for ANCA-associated vasculitis, a group of rare autoimmune diseases. The partnership aims to improve disease understanding and treatment through the analysis of patient material using Evotec's PanOmics platform. Charité will collect biosamples, and Evotec will leverage its M.L.-powered platform to translate research into precision therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.29%
Tags
-
Rhea-AI Summary
Evotec SE (EVT) announced that its license partner, Zhejiang Jingxin Pharmaceutical Co., Ltd, has received approval from the Chinese National Medical Products Administration for the novel insomnia treatment EVT201, also known as Dimdazenil in China. This treatment is a partial positive allosteric modulator of the GABAA receptor with high affinity and moderate efficacy. Evotec will receive double-digit royalties of net sales as well as milestones based on commercial success and further sub-licensing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
Rhea-AI Summary
Evotec SE (EVT) Presents Precision Medicine Capabilities at Capital Markets Day, Highlighting PanOmics, iPSC, and A.I./M.L. Platforms. The company confirms Action Plan 2025 goals and updates progress, showcasing investments of ~€450m into PanOmics and iPSCs, resulting in cumulated revenues of >€1bn and creating a milestone pool of >€15bn. The event emphasizes the introduction of a differentiated offering to shape untapped markets, fostering double-digit growth, and discusses the next big developments in the co-owned pipeline with insights to novel first-in-class targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
-
Rhea-AI Summary
Evotec SE (Frankfurt Stock Exchange: EVT, NASDAQ:EVO) announced 14% revenue growth to € 580.1 m in the first nine months of 2023, driven by strong demand and pipeline progress. Despite a cyber-incident costing € 43.9 m, adjusted Group EBITDA increased by 13% to € 50.2 m. The company also reported multiple new drug discovery agreements, co-owned pipeline progress, and a corporate update on its environmental initiatives. The business outlook for full-year 2023 and mid-term goals for 2025 were confirmed, with a focus on revenue growth and emission reduction targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.55%
Tags
-
Rhea-AI Summary
Evotec SE and Dewpoint Therapeutics have announced a strategic R&D collaboration to advance Dewpoint's oncology pipeline programs using Evotec's data-driven platform. The partnership aims to de-risk and accelerate pre-clinical development candidates to first-in-human clinical studies. Evotec will facilitate the rapid development of Dewpoint's assets using its INDiGO platform. The agreement includes a risk-sharing arrangement and milestone and royalty payments based on program success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
Rhea-AI Summary
Evotec SE announces new partnership with Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund to advance drug discovery and create new therapeutics companies in Singapore.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
-
News
Rhea-AI Summary
Evotec partners with LabCentral, BioLabs, and MBC BioLabs to provide access to its R&D platform for biotech startups.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
-
Rhea-AI Summary
Evotec and Novo Nordisk announce LAB eN², a translational drug discovery accelerator focused on cardiometabolic diseases. Four academic institutions, including Harvard University and Mass General Brigham, have already signed on to participate. LAB eN² aims to accelerate the translation of academic ideas into therapeutic product candidates. It will provide funding, scientific expertise, and technology to advance concepts through pre-clinical proof of concept. Successful candidates may be selected for further investment and development by Novo Nordisk. The prevalence of cardiometabolic diseases is increasing, creating a significant need for new therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
Rhea-AI Summary
Evotec SE announces financial results for H1 2023, with group revenues increasing by 14% to €383.8m. Adjusted Group EBITDA totaled €26.1m. New alliances and collaborations reflect success of growth strategy. Business outlook for FY 2023 confirmed with revenues expected to be in a range of €750-790m and adjusted Group EBITDA guidance range between €60-80m. Cyber-incident in Q2 temporarily reduced revenue growth. Unpartnered research and development expenses expected to be in a range of €60-70m.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
EVTCY